Gordon Parker suggests changes to the DSM-5 criteria for bipolar disorder, and unveils a new screening instrument that aims to separate hypomania from normal happiness.

You will hear about and read research your entire career. Headlines report on positive treatment results, and families come in asking about them. So how should we evaluate research, and what makes a study good or flawed?

For years, we have dreaded seeing our patients develop antipsychotic-induced tardive dyskinesia because there was little we could do about these symptoms. Thankfully, we now have new treatments that produce noticeable improvements in tardive dyskinesia. 

Peter Whitehouse on how to prevent dementia and the limits of pharmacotherapy for cognitive decline. And the word of the day: Ultradian cycling.

This podcast addresses the best treatments for various substance use disorders in pregnant women, outlines which substances have the highest potential for producing negative pregnancy outcomes.

Experts tackle various research topics in the field of child psychiatry, from the risk of stimulant-induced psychosis in youth with ADHD to the efficacy and safety of SSRIs and SNRIs for young people with psychiatric disorders.

On average, people with schizophrenia die 20–25 years sooner than those without schizophrenia. How can we spot metabolic side effects early in our patients, and what should we be looking for exactly?

Several studies are discussed in this podcast, including one that suggests modest clinical utility for short-term use of melatonin in children and adolescents struggling with sleep-onset insomnia.

A recent study that explored long-term treatment outcomes for children with OCD is discussed with a bonus CME test.